Clinicopathological factors affecting prognosis in marginal zone lymphoma in Asian patients: a cohort study.

The six patients on rituximab who had complete or partial response to the treatment comprised three patients who had stage 4 disease and three patients who had stage 1 disease. Marginal zone B-cell lymphoma (MZL) refers to a group of lymphomas arising from B lymphocytes located in the marginal zone of secondary lymphoid follicles. In the extranodal MZL cohort, patients receiving systemic therapy had an increased risk of disease progression (HR 2.18, 95% CI 1.13-4.23, I p i = 0.020) compared against patients receiving local therapy. Compared to lung MZL and other MZL subtypes, gastric MZL and orbital MZL were more likely to present with earlier Ann Arbor stage at diagnosis ( I p i < 0.0001) (Figure 1(A)). [Extracted from the article]